Search

for
Search:

Did you mean JAK3 Inhibitor?

GlossaryJAK3 Inhibitor

blocks an enzyme involved in immune response and inflammation

A JAK3 Inhibitor, also known as a Janus Kinase 3 Inhibitor, is a type of medication that blocks the activity of the JAK3 enzyme. This enzyme is involved in the signaling pathways that regulate immune responses and inflammation. By inhibiting JAK3, these drugs can help treat autoimmune diseases and conditions like alopecia areata, where the immune system mistakenly attacks hair follicles.

Related Terms

Sort by

Research

30 / 513 results

Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program

research Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program

January 2024 in “American journal of clinical dermatology”

Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.

research 801 TEC family kinase inhibitors as a novel class of therapeutics in alopecia areata

July 2024 in “Journal of Investigative Dermatology”

ITK inhibitors may effectively treat alopecia areata.

research 0935 Unravelling the role of JAK3/TEC kinase signalling with ritlecitinib in alopecia areata lesional skin and alopecia areata-induced human hair follicles ex vivo

July 2025 in “Journal of Investigative Dermatology”

Ritlecitinib reduces alopecia areata symptoms by blocking JAK3/TEC signaling and T-cell activity.

research 63418 JAK3/TEC kinase pathways are active in alopecia areata lesions, and their inhibition with Ritlecitinib prevents αCD3/αCD28+IL-2 induced immune privilege collapse in healthy hair follicles ex vivo

September 2025 in “Journal of the American Academy of Dermatology”

Ritlecitinib may help treat alopecia areata by protecting hair follicles.

research FDA approves Pfizer's JAK inhibitor for adolescents with alopecia areata hair loss

4 citations , July 2023 in “Nature Medicine”

The FDA approved a new Pfizer drug for hair loss in teens.

research Ritlecitinib in Alopecia Areata: A 24‐Week Real‐World Experience Contrasting JAK Inhibitor‐Naïve and JAK Inhibitor‐Experienced Patients

December 2025 in “The Journal of Dermatology”

Ritlecitinib effectively reduces hair loss in JAK inhibitor-naïve alopecia areata patients.

research Efficacy and safety of ritlecitinib, an oral JAK3/TEC family kinase inhibitor, in adolescent and adult patients with alopecia totalis and alopecia universalis

7 citations , September 2024 in “The Journal of Dermatology”

Ritlecitinib helps regrow hair in people with alopecia totalis and universalis and is safe to use.

research Inhibition of T-cell activity in alopecia areata: recent developments and new directions

4 citations , November 2023 in “Frontiers in immunology”

New treatments targeting T-cell pathways are needed for better alopecia areata management.

research 42004 Scalp, eyebrow, and eyelash hair regrowth with continued ritlecitinib treatment among patients with alopecia areata without target efficacy response at Week 24: post hoc analysis of the ALLEGRO phase 2b/3 study

1 citations , September 2023 in “Journal of the American Academy of Dermatology”

Continued ritlecitinib treatment can lead to hair regrowth in some patients with alopecia areata who initially don't respond.

research 42005 Sustained scalp, eyebrow, and eyelash hair regrowth with ritlecitinib through Week 48 in patients with alopecia areata: post hoc analysis of the ALLEGRO phase 2b/3 study

1 citations , September 2023 in “Journal of the American Academy of Dermatology”

Ritlecitinib effectively regrows and maintains scalp, eyebrow, and eyelash hair in alopecia areata patients.

research Efficacy and Safety of Switching from Baricitinib to Ritlecitinib in Severe Alopecia Areata

December 2024 in “Clinical and Experimental Dermatology”

Switching to ritlecitinib improves hair regrowth and well-being in severe alopecia areata patients.

research Advances in the mechanism and new therapies of alopecia areata

October 2023 in “International journal of rheumatic diseases”

New treatments targeting the JAK signaling pathway, especially JAK inhibitors, show promise for alopecia areata.

research Ritlecitinib: Efficacy of a Novel Therapy for Severe Alopecia Areata in Patients Aged 12 Years and Older

December 2025 in “Actas Dermo-Sifiliográficas”

Ritlecitinib is effective and safe for treating severe alopecia areata in people aged 12 and older.

research Ritlecitinib Efficacy in Adolescents With Alopecia Areata: A Real‐World Experience

February 2026 in “International Journal of Dermatology”

Ritlecitinib shows promise in improving hair regrowth in adolescents with alopecia areata.

research Multiomics Analysis of the Response to Ritlecitinib in Alopecia Areata Subtypes and Correlation With Efficacy

July 2025 in “Allergy”

Ritlecitinib helps reduce inflammation and promote hair regrowth in alopecia areata, especially in patchy-type cases.

research USE OF RITLECITINIB FOR THE TREATMENT OF ALOPECIA AREATA

December 2023 in “Journal of Ayub Medical College Abbottabad”

Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.

research Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial

227 citations , April 2023 in “The Lancet”

Ritlecitinib effectively treats alopecia areata and is well-tolerated.

research SALT score distribution with ritlecitinib treatment up to 24 months in alopecia areata

2 citations , May 2025 in “Journal of the European Academy of Dermatology and Venereology”

Ritlecitinib improves hair regrowth in alopecia areata over 24 months.

research Real-World Ritlecitinib Treatment of Severe Alopecia Areata (AA) in the US: Patient Characteristics and Physician Satisfaction

July 2025 in “SKIN The Journal of Cutaneous Medicine”

Ritlecitinib effectively improves hair regrowth and physician satisfaction in severe alopecia areata over time.

research Distribution of SALT Scores with Ritlecitinib Treatment up to 24 months from the ALLEGRO Phase 2b/3 and Long-Term Phase 3 Clinical Studies in Alopecia Areata

November 2024 in “SKIN The Journal of Cutaneous Medicine”

Ritlecitinib effectively reduces severe hair loss in alopecia areata over 24 months.

Efficacy of Ritlecitinib in Patients with Alopecia Areata by Extent of Hair Loss: Results from the Phase 2b/3 and Phase 3 ALLEGRO Clinical Trials

research Efficacy of Ritlecitinib in Patients with Alopecia Areata by Extent of Hair Loss: Results from the Phase 2b/3 and Phase 3 ALLEGRO Clinical Trials

November 2024 in “SKIN The Journal of Cutaneous Medicine”

Ritlecitinib effectively promotes hair regrowth in severe and very severe alopecia areata.

research Sustained Scalp, Eyebrow, and Eyelash Hair Regrowth with Ritlecitinib Through Week 48 in Patients with Alopecia Areata: Post-Hoc Analysis of the ALLEGRO Phase 2b/3 Study

November 2023 in “SKIN The Journal of Cutaneous Medicine”

Ritlecitinib effectively maintains hair regrowth in alopecia areata patients.

research Alopecia areata: Ritlecitinib generates substantial re-growth of scalp hair

October 2023

Ritlecitinib significantly regrows scalp hair in people with alopecia areata.

research Hair Loss Profiles and Ritlecitinib Efficacy in Patients with Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study

September 2023 in “Dermatology and therapy”

Ritlecitinib effectively improves hair growth in alopecia areata patients, regardless of hair loss pattern.

research 455 Beyond Immunity: TEC and JAK3 Kinase Activation in Melanocytes Drives Inflammation in Vitiligo

November 2025 in “Journal of Investigative Dermatology”

TEC kinases may help cause inflammation in vitiligo and could be targeted for treatment.

research 046 Analysing the mechanistic basis of Ritlecitinib’s therapeutic effects in Alopecia Areata

November 2025 in “Journal of Investigative Dermatology”

Ritlecitinib effectively treats severe Alopecia Areata by reducing harmful immune activity in the skin.

research ADVERSE EFFECTS OF RITLECITINIB IN ADULTS AND ADOLESCENTS WITH ALOPECIA AREATA: A LITERATURE REVIEW

December 2025 in “International Journal of Innovative Technologies in Social Science”

Ritlecitinib is generally safe for long-term use, with mostly mild side effects.

research Efficacy and Safety of Ritlecitinib in the Asian Subpopulation of the ALLEGRO ‐2b/3 and ALLEGRO ‐ LT Clinical Studies for Alopecia Areata

February 2026 in “The Journal of Dermatology”

Ritlecitinib effectively regrows scalp, eyebrow, and eyelash hair in Asians with alopecia areata and is safe.

research Cost‐Effectiveness Analysis of Ritlecitinib Compared With No Treatment in Patients With Severe Alopecia Areata in Japan

March 2026 in “The Journal of Dermatology”

Ritlecitinib is cost-effective for severe alopecia areata in Japan.

The FDA Approves Litfulo® (Ritlecitinib) for the Treatment of Severe Alopecia Areata in Adolescents and Adults

research La FDA aprueba Litfulo® (ritlecitinib) para el tratamiento de la alopecia areata grave en adolescentes y adultos

September 2023 in “Medicina Estética Revista Científica de la Sociedad Española de Medicina Estética (SEME)”

The FDA approved Litfulo® for treating severe alopecia areata in people aged 12 and older.